After years of pressure from patients and experts, one of the world’s most misunderstood hormonal disorders has a new name.

Polycystic ovary syndrome, long known as PCOS, will now be called polyendocrine metabolic ovarian syndrome, or PMOS, according to reports on a decade-plus international consultation. The change targets more than branding. Supporters argue the old name misled patients and clinicians by narrowing attention to ovarian cysts while missing the condition’s broader hormonal and metabolic impact.

That matters at enormous scale. Reports indicate the condition affects about one in eight women and an estimated 170 million women worldwide. For years, patient advocates have said the label “PCOS” fueled confusion, delayed recognition, and deepened isolation for people trying to understand symptoms and seek treatment. The new term aims to reflect the full picture more clearly: an illness tied not only to the ovaries, but also to endocrine and metabolic health.

The renaming effort signals a larger shift: patient experience now shapes not just treatment debates, but the language medicine uses to define disease.

Key Facts

  • PCOS has been renamed polyendocrine metabolic ovarian syndrome, or PMOS.
  • Reports indicate the condition affects roughly one in eight women.
  • Estimates suggest about 170 million women worldwide live with the disorder.
  • The new name follows more than a decade of global consultation shaped by patient perspectives.

The renaming also exposes a deeper problem in women’s health: when a diagnosis sounds incomplete, care can become incomplete too. Sources suggest campaigners spent years arguing that the old term caused undue suffering because it failed to capture the condition’s complexity. A more precise name will not solve gaps in diagnosis or treatment on its own, but advocates hope it will sharpen public understanding and push clinicians to look beyond outdated assumptions.

What happens next will determine whether PMOS becomes more than a new acronym. Health systems, doctors, researchers, and patient groups now face the harder task of turning new language into better recognition, clearer information, and more consistent care. For millions living with the condition, the real test starts now: whether a name change can finally open the door to earlier diagnosis and less confusion.